BR112015022207A2 - forma cristalina do composto i, formas cristalinas de sais do composto i e método para o tratamento de melanoma - Google Patents

forma cristalina do composto i, formas cristalinas de sais do composto i e método para o tratamento de melanoma

Info

Publication number
BR112015022207A2
BR112015022207A2 BR112015022207A BR112015022207A BR112015022207A2 BR 112015022207 A2 BR112015022207 A2 BR 112015022207A2 BR 112015022207 A BR112015022207 A BR 112015022207A BR 112015022207 A BR112015022207 A BR 112015022207A BR 112015022207 A2 BR112015022207 A2 BR 112015022207A2
Authority
BR
Brazil
Prior art keywords
compound
salts
crystalline
treating melanoma
crystalline form
Prior art date
Application number
BR112015022207A
Other languages
English (en)
Other versions
BR112015022207A8 (pt
Inventor
J Jacobs Martin
C Wanger Ralph
J Bierlmaier Stephen
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of BR112015022207A2 publication Critical patent/BR112015022207A2/pt
Publication of BR112015022207A8 publication Critical patent/BR112015022207A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

resumo forma cristalina do composto i, formas cristalinas de sais do composto i e mtodo para o tratamento de melanoma. este pedido refere-se a v rios sais e formas em estado s¢lido de um composto (i). o pedido refere-se igualmente a composi‡äes farmacˆuticas e usos terapˆuticos destes materiais e composi‡äes.
BR112015022207A 2013-03-11 2014-03-11 forma cristalina do composto i, formas cristalinas de sais do composto i e uso do composto i BR112015022207A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776081P 2013-03-11 2013-03-11
PCT/US2014/023110 WO2014164648A2 (en) 2013-03-11 2014-03-11 Solid state forms of a quinazoline derivative and its use as a braf inhibitor

Publications (2)

Publication Number Publication Date
BR112015022207A2 true BR112015022207A2 (pt) 2017-07-18
BR112015022207A8 BR112015022207A8 (pt) 2018-01-23

Family

ID=50771322

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022207A BR112015022207A8 (pt) 2013-03-11 2014-03-11 forma cristalina do composto i, formas cristalinas de sais do composto i e uso do composto i

Country Status (15)

Country Link
US (3) US9353097B2 (pt)
EP (1) EP2956454A2 (pt)
JP (1) JP2016512516A (pt)
KR (1) KR20150132118A (pt)
CN (1) CN105051039A (pt)
AU (2) AU2014249158B2 (pt)
BR (1) BR112015022207A8 (pt)
CA (1) CA2901204C (pt)
EA (1) EA025561B1 (pt)
HK (2) HK1217193A1 (pt)
IL (1) IL241239A0 (pt)
MX (1) MX2015012318A (pt)
NZ (1) NZ710600A (pt)
TW (1) TW201512192A (pt)
WO (1) WO2014164648A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2956454A2 (en) 2013-03-11 2015-12-23 Ignyta, Inc. Solid state forms of a quinazoline derivative and its use as a braf inhibitor
US10799503B2 (en) 2016-12-01 2020-10-13 Ignyta, Inc. Methods for the treatment of cancer
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
CN111153860B (zh) * 2019-12-30 2021-06-29 广州六顺生物科技股份有限公司 一种喹唑啉类化合物的晶型及其制备方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244120A1 (en) * 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
MX2010010172A (es) * 2008-03-17 2010-11-25 Ambit Biosciences Corp Derivados de quinazolina como moduladores de quinasa raf y metodos de uso de los mismos.
AU2012240240A1 (en) * 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
EP2956454A2 (en) 2013-03-11 2015-12-23 Ignyta, Inc. Solid state forms of a quinazoline derivative and its use as a braf inhibitor

Also Published As

Publication number Publication date
HK1217333A1 (zh) 2017-01-06
MX2015012318A (es) 2016-04-15
WO2014164648A2 (en) 2014-10-09
WO2014164648A3 (en) 2014-11-27
US9987281B2 (en) 2018-06-05
US20150376171A1 (en) 2015-12-31
EP2956454A2 (en) 2015-12-23
AU2016204294A1 (en) 2016-07-14
EA025561B1 (ru) 2017-01-30
BR112015022207A8 (pt) 2018-01-23
US9353097B2 (en) 2016-05-31
AU2014249158B2 (en) 2016-07-28
KR20150132118A (ko) 2015-11-25
AU2016204294B2 (en) 2017-08-31
US20170290833A1 (en) 2017-10-12
IL241239A0 (en) 2015-11-30
CN105051039A (zh) 2015-11-11
WO2014164648A4 (en) 2015-01-29
TW201512192A (zh) 2015-04-01
JP2016512516A (ja) 2016-04-28
EA201591259A1 (ru) 2016-02-29
US20160280698A1 (en) 2016-09-29
AU2014249158A1 (en) 2015-09-17
CA2901204C (en) 2018-07-10
US9718810B2 (en) 2017-08-01
CA2901204A1 (en) 2014-10-09
NZ710600A (en) 2017-01-27
AU2016204294B9 (en) 2017-09-21
HK1217193A1 (zh) 2016-12-30

Similar Documents

Publication Publication Date Title
CY1122222T1 (el) Συνθεση βορονικων αλατων και χρησεις αυτων
BR112016011065A2 (pt) Composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
EA201790766A1 (ru) Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
BR112016017996A2 (pt) 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso
BR112015022207A2 (pt) forma cristalina do composto i, formas cristalinas de sais do composto i e método para o tratamento de melanoma
BR112017009194A2 (pt) tetra-hidropiranos substituídos e método de uso
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
UA115773C2 (uk) Пірольні сполуки, спосіб їх одержання та фармацевтична композиція, що їх містить (варіанти)
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
AR103680A1 (es) Inhibidores selectivos de bace1
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
BR112019006030A2 (pt) formas cristalinas e de sal de compostos agonistas de ppar
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
CL2015002488A1 (es) Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
EP3492468A4 (en) HETEROCYCLIC COMPOUND AS A JAK INHIBITOR, SALTS AND THERAPEUTIC USE THEREOF
EA201500931A1 (ru) Производные пиридин-4-ила
WO2014153495A3 (en) Novel stat3 inhibitors
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements